UnitedHealth Stock Faces Margin Pressure Despite Attractive Valuation
UnitedHealth Group's stock has shown an attractive long-term valuation, with a fair-value upside of 32.7% to $503.78 per share, according to FinQL. However, its near-term chart remains firmly defensive due to collapsing net margins.
The company's revenue has expanded from $287.60B in 2021 to $447.96B in 2025, but profitability has deteriorated sharply. Analysts project a recovery of EPS from $19.76 in FY2026 to $26.22 in FY2028, contingent on stabilizing medical costs and rebuilding OptumHealth margins.
The bear case suggests that the earnings engine has not yet proven it can absorb higher healthcare utilization, with net income declining from $22.38B in 2023 to $12.06B in 2025. Regulatory exposure, policy changes, and reimbursement reforms could also pressure risk adjustment and operating flexibility.